Monthly information on share capital and company voting rights
Cellectis has reported its monthly share capital and voting rights information as of October 31, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis has reported its monthly share capital and voting rights information as of October 31, 2024. The company disclosed a total of 100,093,873 shares in the capital and 88,569,210 voting rights. This disclosure is made in compliance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth under ISIN code FR0010425595.
Details
News Market Reaction – CLLS
The recorded move for CLLS in the trading session of this news was -1.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 10/31/2024 | 100,093,873 | 88,569,210 |
For further information on Cellectis, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.